Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products

Must Read

List of United Bank for Africa (UBA) Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number that usually identifies both the bank and the branch where an account is held. The sort...

List of Access Bank Sort Codes & Branches (with addresses) in Nigeria

The sort code is a number which usually identifies both the bank and the branch where an account is...

How To Block Your Bank Account And SIM Card In Case Of Emergency

Losing your phone and wallet or having them stolen can be very frustrating. However, in case that happens to...
- Advertisement -

Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m.

Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products – www.brandspurng.com

“We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches,” said John Reed, M.D., Ph.D, Global Head of Research & Development at Sanofi.

“Kiadis’ vision is to bring novel cell-based medicines to people with life-threatening diseases, and this transaction will help achieve that vision,” said Arthur Lahr, Chief Executive Officer of Kiadis. “After the discontinuation of our lead product candidate and subsequent reorganization in 2019, we restarted Kiadis in 2020 as an entirely new company focused solely on the proprietary and differentiated NK-cell platform that we obtained through the acquisition of Cytosen Therapeutics.

“Sanofi’s offer is a clear testimony to the uniqueness of our NK-cell platform and the rapid success of Kiadis’ transformation. The Kiadis Boards unanimously believe that Sanofi has the resources and financial strength to accelerate development of our NK-cell products, to the benefit of patients. We believe this transaction represents compelling value to shareholders and offers a fair reflection of the potential of our platform and pipeline, given the risk/reward profile typical to biotech and the capital required to execute our business plan. Finally, this transaction will provide excellent career opportunities for our employees, who will be viewed by Sanofi as their internal cell-therapy experts.”

Innovative K-NK cell platform
- Advertisement -

Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf’ NK cells from a healthy donor. NK cells seek and identify malignant cancer cells and have broad application across various tumor types. The platform has the potential to make products rapidly and economically available for a broad patient population across a wide range of indications.

Read Also:  Facebook Invests Additional $100 Million To Support News Industry During The Coronavirus Crisis

Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.

Complementary strong science to generate first-in-class medicines and strategic fit across core therapeutic areas

Sanofi’s research, development, and commercial expertise will be leveraged to advance Kiadis’ pipeline, which includes NK cell-based medicines for the treatment of patients undergoing hematopoietic stem cell transplant, liquid and solid tumours, as well as infectious disease.

Read Also:  Facebook Invests Additional $100 Million To Support News Industry During The Coronavirus Crisis

In July 2020, Sanofi licensed Kiadis’ pre-clinical K-NK004 program for potential combination for multiple myeloma.

- Advertisement -

Kiadis’ pipeline of NK cell therapies includes:

K-NK002 is in Phase 2 clinical study evaluating NK cells to prevent post-transplant relapse in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes. The Phase 2 trial will be conducted in collaboration with premier U.S. transplant centres.

K-NK003 is a Phase 1 study evaluating NK cells for patients with relapsed or refractory AML.

KNK-ID-101 is a program evaluating the properties of K-NK cells and their suitability to fight SARS-CoV-2 and the option to develop K-NK cells as a post-exposure pre-emptive therapy for COVID-19 in high-risk patients. Kiadis plans to initiate a Phase 1/2a clinical trial evaluating the use of K-NK cells to treat COVID-19 patients with government grant funding.

Accelerates the clinical development and broadens patient reach of current Kiadis pipeline
- Advertisement -

Subject to the completion of the public offer, Sanofi will provide the resources and capabilities necessary to accelerate the development of current Kiadis programs for the treatment of blood tumours, solid cancers, and infectious diseases, maximizing their potential to the benefit of patients.

- Advertisement -
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand SpurSanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand Spur

Subscribe to BrandSpur Ng

Subscribe for latest updates. Signup to best of brands and business news, informed analysis and opinions among others that can propel you, your business or brand to greater heights.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand SpurSanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand Spur

Latest News

Ekiti State Governor commissions the Sexual Assault Referral Centre, Moremi Clinic (Photos)

On the 25th November 2020, the Ekiti State Governor, Dr. Kayode Fayemi commissioned the Sexual Assault Referral Centre (MOREMI...

Video: Construction of a 4-lane dual carriage New Ado-Iyin-Aramoko-Itawure road is ongoing

Construction of a 4-lane dual carriage New Ado-Iyin-Aramoko-Itawure road is ongoing This road project is part of Governor Kayode Fayemi initiatives to improve inter-connectivity of...

Ogun State facilitates more capital to boost Fish Production

Ogun State Ministry of Industry, Trade and Investment will continue to facilitate access to capital and work with relevant agencies to build the capacity...

Abiodun Reads Riots Act to Ogun State Water Corporation

The Governor of Ogun State, Prince Dapo Abiodun, has given a marching order to the General Manager of the Ogun State water corporation, Engineer...

Lagos Examinations Board reschedules Y2020 BECE Resit Test

The Lagos State Examinations Board has rescheduled the Year 2020 Basic Education Certificate Examination (BECE) resit test earlier fixed for Saturday, December 5, 2020,...
- Advertisement -
BrandsPur Weekly Cartoons
- Advertisement -Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand SpurSanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products - Brand Spur